Tranzyme refocus failure confirmed as TZP-102 crashes again

Tranzyme Pharma is stopping a second clinical trial with TZP-102, an oral ghrelin agonist, as a treatment for diabetic gastroporesis because it failed to outperform placebo.

Tranzyme Pharma is stopping a second clinical trial with TZP-102, an oral ghrelin agonist, as a treatment for diabetic gastroporesis because it failed to outperform placebo.

Earlier this year, Tranzyme was forced to "switch" its focus to TZP-102 after its previous lead drug candidate, the intravenous...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category